Cutaneous squamous cell carcinoma (cSCC) is the second most common skin cancer and represents a major global health burden. Approximately 50% of cSCC patients develop primary resistance and 20% will develop secondary resistance to immune checkpoint inhibitors (ICI). There are limited biomarkers that reflect the tumor dynamics predictive of response to ICI therapy, and therefore we need to explore new biomarkers that can better understand the cSCC tumor microenvironment (TME).

Niyati Jhaveri¹, Dmytro Klymyshyn¹, Bassem B. Cheikh¹, James Monkman², Dan Winkowski³, James Mansfield³, Subham Basu⁴, Michael Prater⁴, Nadine Nelson⁴, Gabrielle Belz², Oliver Braubach¹, Arutha Kulasinghe²

1. Akoya Biosciences, Menlo Park, CA
2. The University of Queensland, Brisbane, Australia
3. Visiopharm A/S, Horsholm, Denmark
4. Abcam, Cambridge, United Kingdom